Ichnos Sciences SA has a total of 56 patent applications. It increased the IP activity by 650.0%. Its first patent ever was published in 2006. It filed its patents most often in Australia, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are APOGENIX AG, TRUBION PHARMACEUTICALS INC and ZESTAGEN S A.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 25 | |
#2 | EPO (European Patent Office) | 8 | |
#3 | WIPO (World Intellectual Property Organization) | 5 | |
#4 | EAPO (Eurasian Patent Organization) | 4 | |
#5 | Japan | 4 | |
#6 | Singapore | 3 | |
#7 | United States | 3 | |
#8 | Hong Kong | 2 | |
#9 | Israel | 1 | |
#10 | Mexico | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Organic fine chemistry | |
#5 | Chemical engineering |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Microorganisms | |
#5 | Analysing materials | |
#6 | Fermentation | |
#7 | Heterocyclic compounds | |
#8 | Separation |
# | Name | Total Patents |
---|---|---|
#1 | Blein Stanislas | 20 |
#2 | Lissilaa Rami | 15 |
#3 | Ollier Romain | 10 |
#4 | Hou Samuel | 10 |
#5 | Skegro Darko | 8 |
#6 | Bertschinger Martin | 7 |
#7 | Moretti Pierre | 7 |
#8 | Aebischer-Gumy Christel | 7 |
#9 | Back Jonathan Albert | 6 |
#10 | Attinger Antoine | 6 |
Publication | Filing date | Title |
---|---|---|
WO2021013689A1 | Lyophilized antibody formulation | |
WO2020182984A2 | Non-consensus glycosylation of bispecific antibodies | |
WO2020079280A1 | T cell redirecting bispecific antibodies for the treatment of squamous cell cancers | |
EP3791931A1 | Bispecific antibodies for the treatment of solid tumors | |
EP3786174A1 | Methods for antibody purification | |
EP3766481A1 | Liquid antibody formulation | |
AU2018338045A1 | mPGES-1 inhibitor for the treatment of osteoarthritis pain | |
EP3630778A1 | Novel inhibitors of map4k1 | |
SG10201912545PA | T cell redirecting bispecific antibodies for the treatment of egfr positive cancers |